Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

USA - NASDAQ:HALO - US40637H1095 - Common Stock

64.1 USD
-1.01 (-1.55%)
Last: 10/10/2025, 9:32:43 PM
63.76 USD
-0.34 (-0.53%)
After Hours: 10/10/2025, 9:32:43 PM
Fundamental Rating

8

HALO gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HALO could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HALO was profitable.
HALO had a positive operating cash flow in the past year.
HALO had positive earnings in each of the past 5 years.
HALO had a positive operating cash flow in each of the past 5 years.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

The Return On Assets of HALO (27.13%) is better than 97.76% of its industry peers.
Looking at the Return On Equity, with a value of 167.48%, HALO belongs to the top of the industry, outperforming 99.63% of the companies in the same industry.
With an excellent Return On Invested Capital value of 28.55%, HALO belongs to the best of the industry, outperforming 98.88% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HALO is above the industry average of 15.47%.
The last Return On Invested Capital (28.55%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 27.13%
ROE 167.48%
ROIC 28.55%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

With an excellent Profit Margin value of 47.28%, HALO belongs to the best of the industry, outperforming 98.88% of the companies in the same industry.
In the last couple of years the Profit Margin of HALO has declined.
Looking at the Operating Margin, with a value of 57.92%, HALO belongs to the top of the industry, outperforming 99.81% of the companies in the same industry.
HALO's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 84.20%, HALO belongs to the best of the industry, outperforming 87.13% of the companies in the same industry.
In the last couple of years the Gross Margin of HALO has grown nicely.
Industry RankSector Rank
OM 57.92%
PM (TTM) 47.28%
GM 84.2%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
HALO has less shares outstanding than it did 1 year ago.
HALO has less shares outstanding than it did 5 years ago.
The debt/assets ratio for HALO has been reduced compared to a year ago.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 5.15 indicates that HALO is not in any danger for bankruptcy at the moment.
The Altman-Z score of HALO (5.15) is better than 74.63% of its industry peers.
HALO has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as HALO would need 2.79 years to pay back of all of its debts.
HALO has a Debt to FCF ratio of 2.79. This is amongst the best in the industry. HALO outperforms 94.03% of its industry peers.
HALO has a Debt/Equity ratio of 4.54. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HALO (4.54) is worse than 81.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.54
Debt/FCF 2.79
Altman-Z 5.15
ROIC/WACC3.25
WACC8.79%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

HALO has a Current Ratio of 8.36. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.36, HALO is in the better half of the industry, outperforming 74.44% of the companies in the same industry.
A Quick Ratio of 7.01 indicates that HALO has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.01, HALO is doing good in the industry, outperforming 69.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.36
Quick Ratio 7.01
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.41% over the past year.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
The Revenue has grown by 34.97% in the past year. This is a very strong growth!
HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%

3.2 Future

HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.27% yearly.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.85% yearly.
EPS Next Y48.66%
EPS Next 2Y38.6%
EPS Next 3Y33.13%
EPS Next 5Y18.27%
Revenue Next Year31.57%
Revenue Next 2Y27.61%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 12.37, HALO is valued correctly.
96.83% of the companies in the same industry are more expensive than HALO, based on the Price/Earnings ratio.
HALO is valuated cheaply when we compare the Price/Earnings ratio to 27.02, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 7.89 indicates a rather cheap valuation of HALO.
98.13% of the companies in the same industry are more expensive than HALO, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.57. HALO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.37
Fwd PE 7.89
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.27% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 96.64% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.87
EV/EBITDA 10.58
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 33.13% in the coming years.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y38.6%
EPS Next 3Y33.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HALO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (10/10/2025, 9:32:43 PM)

After market: 63.76 -0.34 (-0.53%)

64.1

-1.01 (-1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners102.63%
Inst Owner Change0%
Ins Owners0.85%
Ins Owner Change0.07%
Market Cap7.50B
Analysts75
Price Target76.12 (18.75%)
Short Float %10.19%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.03%
Min EPS beat(2)14.79%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)16.87%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)12.25%
EPS beat(12)10
Avg EPS beat(12)12.69%
EPS beat(16)13
Avg EPS beat(16)10.59%
Revenue beat(2)2
Avg Revenue beat(2)12.25%
Min Revenue beat(2)11.69%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.78%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)5.19%
Revenue beat(12)7
Avg Revenue beat(12)3.36%
Revenue beat(16)9
Avg Revenue beat(16)2.8%
PT rev (1m)4.37%
PT rev (3m)5.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.57%
EPS NY rev (1m)0.47%
EPS NY rev (3m)12.09%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)1.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.4%
Valuation
Industry RankSector Rank
PE 12.37
Fwd PE 7.89
P/S 6.36
P/FCF 13.87
P/OCF 13.69
P/B 22.53
P/tB N/A
EV/EBITDA 10.58
EPS(TTM)5.18
EY8.08%
EPS(NY)8.13
Fwd EY12.68%
FCF(TTM)4.62
FCFY7.21%
OCF(TTM)4.68
OCFY7.31%
SpS10.08
BVpS2.84
TBVpS-3.85
PEG (NY)0.25
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 27.13%
ROE 167.48%
ROCE 35.56%
ROIC 28.55%
ROICexc 39.96%
ROICexgc 93.15%
OM 57.92%
PM (TTM) 47.28%
GM 84.2%
FCFM 45.87%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 4.54
Debt/FCF 2.79
Debt/EBITDA 1.97
Cap/Depr 8.67%
Cap/Sales 0.6%
Interest Coverage 250
Cash Conversion 71.66%
Profit Quality 97.02%
Current Ratio 8.36
Quick Ratio 7.01
Altman-Z 5.15
F-Score8
WACC8.79%
ROIC/WACC3.25
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
EPS Next Y48.66%
EPS Next 2Y38.6%
EPS Next 3Y33.13%
EPS Next 5Y18.27%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%
Revenue Next Year31.57%
Revenue Next 2Y27.61%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
EBIT growth 1Y68.72%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.62%
EBIT Next 3Y39.07%
EBIT Next 5Y15.57%
FCF growth 1Y84.66%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y79.07%
OCF growth 3Y16.96%
OCF growth 5YN/A